Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBM26 antisense RNA 1 (RBM26-AS1) is a long non-coding RNA located on chromosome 13q31.1, transcribed antisense to the protein-coding RBM26 gene[4]. While previously annotated as non-protein coding, recent studies demonstrate that RBM26-AS1 may encode short micropeptides that promote colon cancer cell growth by enhancing nucleocytoplasmic transport and protein processing in the endoplasmic reticulum[2]. There is currently no known specific biological function assigned to the lncRNA itself in normal physiology, though it likely regulates gene expression of RBM26 and possibly other related genes, consistent with mechanisms observed for antisense RNAs[3][7]. As of now, RBM26-AS1 is not considered a classical therapeutic target, and no clinical drugs interact with it directly[2][4][7].
For antisense oligonucleotides (ASOs) targeting antisense RNAs: RNA degradation via RNase H, modulation of RNA stability, interference with mRNA translation. The RBM26-AS1-encoded micropeptide may enhance nucleocytoplasmic transport and ER protein processing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RBM26 antisense RNA 1 (RBM26-AS1).